Gastrokinetic bicyclic benzamides of 3- or 4-substituted 4-(aminomethyl)- piperdine derivatives
申请人:JANSSEN PHARMACEUTICA N.V.
公开号:EP1206938A1
公开(公告)日:2002-05-22
The present invention of compounds of formula (I)
a stereochemically isomeric form thereof, an N-oxide form thereof or a pharmaceutically acceptable acid addition salt thereof, R1 and R2 taken together form a bivalent radical of formula wherein in said bivalent radicals one or two hydrogen atoms may be substituted with C1-6alkyl; R3 is hydrogen or halo; R4 is hydrogen or C1-6alkyl; R5 is hydrogen or C1-6alkyl; L is C3-6cycloalkyl, C5-6cycloalkanone, C2-6alkenyl, or L is a radical of formula -Alk-R6-, Alk-X-R7, -Alk-Y-C(=O)-R9 , or -Alk-Y-C(=O)-NR11R12 wherein each Alk is C1-12alkanediyl; and R6 is hydrogen, cyano, C1-6alkylsulfonylamino, C3-6cycloalkyl, C5-6cycloalkanone, or a heterocyclic ringsystem; R7 is hydrogen, C1-6alkyl, hydroxyC1-6alkyl, C3-6cycloalkyl, or a heterocyclic ringsystem; X is O, S, SO2 or NR8; said R8 being hydrogen or C1-6alkyl; R9 is hydrogen, C1-6alkyl, C3-6cycloalkyl, C1-6alkyloxy or hydroxy; Y is NR10 or a direct bond; said R10 being hydrogen, or C1-6alkyl; R11 and R12 each independently are hydrogen, C1-6alkyl, C3-6cycloalkyl, or R11 and R12 combined with the nitrogen atom may form an optionally substituted pyrrolidinyl, piperidinyl, piperazinyl or 4-morpholinyl ring. Processes for preparing said products, formulations comprising said products and their use as a medicine are disclosed, in particular for treating conditions which are related to impairment of gastric emptying.
本发明的式(I)化合物
其立体化学异构形式、其 N-氧化物形式或其药学上可接受的酸加成盐,R1 和 R2 共同形成式中的二价基,其中所述二价基中的一个或两个氢原子可被 C1-6 烷基取代;R3 是氢或卤代; R4 是氢或 C1-6烷基; R5 是氢或 C1-6烷基; L 是 C3-6环烷基、C5-6环烷基酮、C2-6烯基,或 L 是式-Alk-R6-、Alk-X-R7、-Alk-Y-C(=O)-R9 或-Alk-Y-C(=O)-NR11R12 的基,其中每个 Alk 是 C1-12 烷二基;R6是氢、氰基、C1-6烷基磺酰氨基、C3-6环烷基、C5-6环烷基酮或杂环环烷;R7是氢、C1-6烷基、羟基C1-6烷基、C3-6环烷基或杂环环烷;X是O、S、SO2或NR8;所述R8是氢或C1-6烷基;R9是氢、C1-6烷基、C3-6环烷基、C1-6烷氧基或羟基;Y 是 NR10 或直接键;所述 R10 是氢或 C1-6 烷基;R11 和 R12 各自独立地是氢、C1-6 烷基、C3-6 环烷基,或 R11 和 R12 与氮原子结合可形成任选取代的吡咯烷基、哌啶基、哌嗪基或 4-吗啉基环。公开了制备上述产品的工艺、包含上述产品的制剂及其作为药物的用途,特别是用于治疗与胃排空障碍有关的疾病。